32results about How to "Retain biological properties" patented technology

The invention discloses a strontium and iron doped hydroxyapatite collagen fiber composite scaffold material and a preparation method thereof. The scaffold material is prepared through compounding collagen fibers having a three dimensional connective porous structure with strontium and iron doped hydroxyapatite with a good drug therapy function. The preparation method mainly comprises the following steps: preparing strontium and iron doped hydroxyapatite through a co-precipitation technology; and compounding the collagen fibers through a dipping-pulling technology. The functional bone restoration scaffold material has excellent biologic performances, very good mechanical strength and toughness and a three dimensional connective macro-porous structure, can deliver drugs to a specific position under the induction of a magnetic field, can restore and treat bone defects induced by various bone diseases, and has wide application prospect in the field of bone restoration materials and biological drugs.

The invention discloses an adult nephroblastoma HANB cell strain with the collection number of CCTCC NO:C201133. A culturing method comprises the following steps of: culturing in-vitro ascites of a patient suffering from poorly-differentiated anaplastic nephroblastoma; passing; freezing for preserving; and recovering; the cell growing speed is high, the quantity is large, the quality is uniform, and a cell culturing method is simple; as proved by evaluation on the biological characteristics such as cell form, protein structure, chromosome, neoplastic rate and the like of the cell strain, the cell strain keeps the biological characteristics of a primary tumor; and due to the usage of the adult nephroblastoma HANB cell strain to the establishment of a nephroblastoma model, a research model is provided for the occurrence, transfer mechanism and clinical treatment of the nephroblastoma.

The invention discloses an undenatured collagen-based biosurfactant using an ionic liquid as a reaction medium and a preparation method thereof. Add 0.03-0.3 parts by weight of long-chain hydrophobic carbonyl compound dissolved in 5-15 parts by weight of organic solvent, react in an ice bath at 4-10°C for 6-10 hours, adjust the pH to 9-10 with acid after the reaction, and then slowly add 0.1 to 0.5 parts by weight of short-chain dibasic acid anhydride dissolved in 5 to 15 parts by weight of organic solvent, while stabilizing the pH at 9 to 10 with alkali, and reacting in an ice bath at 4 to 10°C for 3 to 5 hours. After the reaction, use acid Adjust the pH until precipitation occurs, and the precipitate is washed with deionized water 3 to 5 times with an acid to adjust pH = 4.2 to 4.6 to obtain undenatured collagen-based biosurfactant with high hydrophobic long chain grafting rate, good surface activity and neutral water solubility agent.

The invention discloses an anti-staphylococcus aureus alpha-hemolysin single-chain antibody scFv2 or scFv46, further discloses an anti-staphylococcus aureus alpha-hemolysin recombinant antibody scFv2-Fc or scFv46-Fc containing the scFv2 or scFv46 and a human antibody constant region Fc segment amino acid sequence, and further discloses a universal expression vector sp-Fc / pcDNA3.1 of the fully human anti-staphylococcus aureus alpha-hemolysin recombinant antibody. The nucleic acid sequence of an encoding gene of the universal expression vector is shown in SEQ ID No:13. The invention further discloses a eukaryotic expression vector of the fully human anti-staphylococcus aureus alpha-hemolysin recombinant antibody. The eukaryotic expression vector is obtained by inserting the single-chain antibody into the sp-Fc / pcDNA3.1. The invention further discloses a recombinant expression vector sp-scFv2-Fc / pMH3 or sp-scFv46-Fc / pMH3.

The invention relates to bird flu and Marek's disease dual live vaccine rMDV-HA viral strain and a construction method. H5 subtype bird flu virus SY strain haemagglutinin genes, reticuloendotheliosis disease virus LTR, screening mark genes lac / smGFP and Marek's virus Rispens CVI 988 vaccine strain genome exogenous genes are amplified by adopting reverse transcriptase-polymerase chain reaction or polymerase chain reaction and cloned to plasmid vectors to form recombinant plasmids pHA, pLTR, ploxP-lac / smGFP-loxP, pUP and pDOWN; DNA of transfer vector pMHA plasmids and DNA extracted from cells infected from the Marek's virus Rispens CVI 988 vaccine strain are co-transfected to chick embryo fibroblast; the exogenous genes are inserted to the Marek's virus Rispens CVI 988 vaccine strain genomethrough homologous recombination to form recombinant virus rMDV-HA / GFP with the screening mark genes; and the screening mark genes lac / smGFP of the rMDV-HA / GFP are removed through cre enzyme-mediatedloxP site sequence recombination, and the rMDV-HA / GFP is purified to form the rMDV-HA viral strain. The rMDV-HA viral strain has the advantages of low cost, no pollution and long immunity period, andcan be used as bird flu and Marek's disease dual live vaccine viral strain.

The invention discloses a making method of radioactive iodine-17-allylamine-17-normethoxy geldanamycin in the nuclear medical, tumour and medical agent technical domain, which is characterized by the following: marking the product of 17-allylamine-17-normethoxy geldanamycin through iodine for HSP90; modifying the structure of 17-allylamine-17-normethoxy geldanamycin; guiding radioactive nuclear iodine on the end of double-bond; providing the medical acceptable drug or drug composition to treat tumor or cancer.

The present invention refers to a protein-stabilized metal nanocluster comprising a variant of the helix A of the CTPR. It is also related to its uses for delivering of a drug, for interfering a metabolic reaction, for catalyzing a chemical reaction, as biocatalyst, for detecting an analyte, for phasing crystallographic data set, for cell labeling, for specific protein labeling, as biosensor, as a temperature sensor, as photosensitizer, or for the manufacture of an optoelectronic device.

The procedure for the treatment of purines includes a first phase (1) of electrolytic treatment of the mentioned liquid part in which the metallic nitrates are destroyed by oxidation - reduction and a second phase (2) of physical-chemical treatment of purification and alteration of the properties of the liquid part, eliminating or reducing the pollutants and the CDO; and a third phase (3) in which a substance is added for the use of the resulting product as a base in the manufacture of detergents, medicines and / or cosmetics. The resulting product is sterile, with a total reduction of the metallic nitrates, low nitrogen ammoniacal level, pH between 7.5 to 9.5 and contains phosphorus between 1.5 and 4.5 milligrams / litre, sodium between 750 and 1,800 milligrams / litre, nitrates lower than 1 milligram / litre, ammonia between 2,500 and 4,500 milligrams / litre and its maximum CDO is 5,500 milligrams / litre.